Previous Article | Next Article 
Journal of Virology, December 2000, p. 10994-11000, Vol. 74, No. 23
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Human Immunodeficiency Virus Env-Independent
Infection of Human CD4
Cells
Shen
Pang,1,2
Duan
Yu,1,2
Dong Sung
An,3,4,5
Gayle C.
Baldwin,3
Yiming
Xie,3,4,5
Betty
Poon,3,4,5
Yen-Hung
Chow,1,2
No-Hee
Park,1,2 and
Irvin S. Y.
Chen3,4,5,*
Division of Oral Biology and
Medicine1 and UCLA Dental
Institute,2 UCLA School of Dentistry, and
Department of Medicine,3
Department of Microbiology and
Immunology,4 and UCLA AIDS
Institute,5 UCLA School of Medicine, Los
Angeles, California 90095
Received 20 April 2000/Accepted 19 August 2000
 |
ABSTRACT |
CD4
epithelial cells covering mucosal surfaces serve
as the primary barrier to prevent human immunodeficiency virus type 1 (HIV-1) infection. We used HIV-1 vectors carrying the enhanced green
fluorescent protein gene as a reporter gene to demonstrate that HIV-1
can infect some CD4
human epithelial cell lines with low
but significant efficiencies. Importantly, HIV-1 infection of these
cell lines is independent of HIV-1 envelope proteins. The
Env-independent infection of CD4
cells by HIV-1 suggests
an alternative pathway for HIV-1 transmission. Even on virions bearing
Env, a neutralizing antibody directed against gp120 is incapable of
neutralizing the infection of these cells, thus raising potential
implications for HIV-1 vaccine development.
 |
INTRODUCTION |
Epithelial cells that cover a large
surface area are the initial site of contact between the host and human
immunodeficiency virus (HIV) type 1 (HIV-1) in persons who are exposed
to the virus or virus-infected cells. Therefore, epithelial cells could
play an important role early in HIV-1 infection and in the initial spread of infection. The entry of virus across the epithelial barrier
could significantly influence the risk of mucosal infection and
systemic spread.
HIV infects CD4+ cells by a process of membrane fusion that
is mediated by the interaction of the HIV-1 envelope glycoprotein, gp120, with two cell membrane components, CD4 and a coreceptor belonging to the chemokine receptor family (5, 6, 8, 10).
Previous reports have demonstrated that some CD4
human
cells, including epithelial cells, are also susceptible to HIV-1
infection (9, 11, 14, 16, 24). The binding of gp120 to
chemokine receptors, including CXCR4 and CCR5, or galactosylceramide
(GalCer) has been postulated as the mechanism for HIV-1 infection of
these cells (1, 3, 4, 7, 8, 13, 21). A few results support
such a mechanism: (i) antibodies against gp120 or GalCer inhibited
virus entry into some CD4
epithelial cell lines (3,
13, 22); (ii) molecules that bind to CCR5 or that down-regulate
GalCer blocked infection of CD4
cells (7, 25);
and (iii) HIV-2 could efficiently infect mink lung Mv-1-lu and feline
kidney CCC cells that stably expressed CXCR4 on their cell membranes
(21). However, the above results do not exclude the
possibility that the infection of CD4 cells by HIV-1 may also occur
through alternative mechanisms.
In this study, we tested whether HIV-1 Env
infects
CD4
cells. We prepared a virus carrying the enhanced
green fluorescent protein (EGFP) gene and with no viral envelope
proteins on its surface by transfection. The prepared virus was used to
infect CD4
epithelial cell lines derived from mouth,
kidney, cervix, and prostate gland and a fibroblast cell line. Our
results indicate that CD4
cells from many organs may be
susceptible to HIV-1 infection in an HIV-1 Env-independent fashion.
 |
MATERIALS AND METHODS |
Human cells.
Human cell lines were maintained in RPMI medium
with 10% fetal bovine serum. Primary gingival epithelial cells (normal
human oral keratinocytes [NHOK]) were derived from gingival tissue
obtained from collections from normal donors having periodontal surgery in accordance with procedures approved by the Human Subject Protection Committee at the University of California, Los Angeles. These cells
were maintained and expanded by a previously described procedure (17).
Virus preparation and titration.
Thirty micrograms of
plasmid pNL-4-3-EGFP Env
DNA alone or with plasmids
containing the HIV-1LAI env gene or the
vesicular stomatitis virus (VSV) envelope G glycoprotein (VSV-G) gene
was used to transfect 293T cells in a T175 flask by a calcium
precipitation method. The transfection reagents were purchased from
Promega (Madison, Wis.) (the Profection kit). The transfected cells
were washed twice at 16 h posttransfection, and virus was
collected at days 2 to 4 posttransfection. The collected virus
supernatant was filtered through a 0.45-µm-pore-size filter, and an
aliquot was used for p24 assays. Virus stocks were stored in a
70°C
Revco freezer.
Virus infection and detection of EGFP-positive cells.
Cells
(5 × 103 per well of 24-well culture plates or 2 × 104 per well of 6-well plates) were placed 24 h
before infection. Viruses (p24 counts of 100 ng for each well of
24-well plates or 400 ng for each well of 6-well plates) were added to
each well for 16 h. The viruses were removed, and the cells were
washed with serum-free medium before fresh growth medium was added to
the infected-cell culture. At day 6 postinfection, EGFP-positive cells
were counted visually under a UV microscope or analyzed by flow
cytometric analysis.
Neutralization of gp120 on HIV-1 virions by monoclonal antibody
IgG1-b12.
HIV-1 NL4-3-EGFP with or without HIV-1LAI
envelope proteins, and with a p24 count of 30 ng was mixed with 0.5 µg of immunoglobulin G1 (IgG1)-b12 (NIH AIDS reagent) for 10 min at
37°C and then for 20 min at room temperature before infection. For
the control, virus was incubated under the same conditions without
antibody before infection.
MOLT4 T cells producing NL4-3-EGFP Env
virus.
MOLT4 cells (5 × 106) were infected with
VSV-G-pseudotyped NL4-3-EGFP virus by incubating the cells with 5 ml of
virus supernatant (1,000 ng of p24/ml) in the presence of Polybrene (8 µg/ml; Sigma) at 37°C for 2 h at a multiplicity of infection
of 0.5. The virus supernatant was removed, and the cells were washed
twice with RPMI medium and subsequently cultured for 4 days with 10 ml
of RPMI medium with 10% fetal calf serum, 100 U of penicillin/ml, and
100 µg of streptomycin/ml. The culture medium was replaced with 10 ml
of fresh medium at day 4 after infection. The culture supernatant was
collected at day 8 after infection and filtered through a
0.22-µm-pore-size filter. The p24 level of the supernatant was 1,079 ng/ml. Fifty nine percent of the cells were EGFP positive on day 8 after infection, as analyzed by flow cytometry.
 |
RESULTS |
We noted in initial experiments that HIV-1 virions formed in the
absence of a functional gp120 envelope protein would still give a low
level of infection for some CD4
cell types. We
investigated this finding further by using HIV-1 NL4-3-EGFP
Env
, derived from HIV-1 strain NL4-3, bearing a sensitive
reporter gene for EGFP, and lacking functional gp120. HIV-1 carrying
the EGFP reporter gene and with a deletion of the Env proteins was generated by cotransfection. The plasmid used for transfection to
generate HIV-1 NL4-3-EGFP Env
was prepared by deleting
part of env (between the two BglII sites in
gp120, from nucleotides 7032 to 7612 of HIV-1 NL4-3 [National Center
for Biotechnology Information accession no. M19921]), resulting in a
deletion and a frameshift in the Env gp160 reading frame. Thus, gp160,
the precursor of viral envelope glycoproteins gp120 and gp41, would not
be produced. The nef sequence was also partially deleted
(222 bp from the start codon), and EGFP was inserted to replace the
deleted nef sequence (Fig.
1A). Virus was prepared by transfection
of the human 293T cell line (a human embryonic kidney epithelial cell
line transformed by simian virus 40 large T antigen and adenovirus). As
controls, we prepared two other viruses bearing HIV-1LAI
Env proteins or the VSV-G gene by cotransfecting 293T cells with
pNL4-3-EGFP Env
and plasmids carrying the
HIV-1LAI env gene or the VSV-G gene, respectively (Fig. 1B). VSV-G-pseudotyped viral particles have a wide
target cell spectrum (18). Using semiquantitative reverse transcription-PCR, we found that all three virions were produced from
transfected 293T cells with comparable efficiencies (Fig. 1C). Env is
not required for virus generation, consistent with previous reports
(20, 23).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 1.
Construction of HIV-1 NL4-3-EGFP Env . (A)
Structure of HIV-1 NL4-3-EGFP Env . (B) Diagram of the
preparation of NL4-3-EGFP viruses with no envelope protein, with
HIV-1LAI envelope proteins, or with VSV-G. LTR, long
terminal repeat. (C) Reverse transcription-PCR quantification of virus
stocks. Viral RNA was obtained from virus stocks with 1 ng of p24. This
amount of virus represents 5 × 103 to 5 × 104 RNA molecules.
|
|
We infected two CD4
epithelial cell lines derived from an
oral carcinoma, Tu139 and Tu177 (17), with these viruses.
The kidney epithelial cell line 293T was also tested. HIV-1 bearing VSV-G efficiently infected all three cell lines, as assayed by flow
cytometric analysis of EGFP-positive cells. At 3 to 6 days postinfection, EGFP-positive cells were also detected in the Tu139 and
Tu177 cell lines infected with the other two viruses, one containing
HIV-1LAI Env proteins and one containing no HIV-1 Env proteins. The oral epithelial cell lines Tu139 and Tu177 showed high
levels of infection, with greater than 5% of cells being positive
(Fig. 2). Virus with HIV-1 Env proteins
or with no Env proteins showed very low levels of infection of 293T
cells, occasionally visualized by fluorescence microscopy (Fig. 3 and
4). To confirm that the observed EGFP expression was due to HIV-1
infection, zidovudine (AZT), a reverse transcriptase inhibitor, was
added to a parallel set of infected cultures. The presence of AZT
resulted in nearly complete elimination of EGFP-positive cells (Fig.
2). Thus, the expression of EGFP in infected CD4
cells
results from stable HIV-1 infection.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 2.
Infection of CD4 epithelial cell lines by
HIV-1 NL-4-3-EGFP Env . Cells (2 × 104)
were plated in each well of six-well culture plates 24 h before
infection. Cells were infected as described in Materials and Methods
with 400 µg of p24 per well. At day 6 postinfection, cells from three
of the cell lines, 293T, Tu139, and Tu177, infected with viruses
NL4-3-EGFP Env , NL4-3-EGFP Env with
HIV-1LAI envelope proteins, and NL4-3-EGFP
Env with VSV-G, were collected for flow cytometric
analysis to determine the percentage of EGFP-positive cells present.
AZT (5 µM), a reverse transcriptase inhibitor, was added to parallel
cell culture dishes 30 min prior to viral infection; this concentration
of AZT was maintained in the culture medium throughout the test
period.
|
|
To assess whether CD4
cells from other tissues were
susceptible to HIV-1 infection, we used each of the three viruses to
infect other CD4
cell lines, including the fibrosarcoma
cell line HT1080 (derived from the tissue adjacent to the acetabulum;
ATCC CCL-121), the prostate cancer cell line DU145, and the cervical
cancer cell line HeLa and its derivative, HeLa-CD4 (with expression of
the CD4 molecule). All of these cells, except for HT1080, are
epithelial cell lines; HT1080 is a fibrosarcoma cell line with
epithelial morphology. As described above, Tu139 and Tu177 could be
infected (Fig. 3A and
4A). Significant levels of infection were
also seen in two other cell lines, HT1080 and DU145, with greater than
1% of cells being infected (Fig. 3B and 4A). As expected, the HeLa-CD4 cell line was highly susceptible only to NL4-3-EGFP Env
with VSV-G or HIV-1LAI Env proteins (Fig. 3B).

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 3.
Infection of CD4 cells by HIV-1. (A)
Infection of Tu139, Tu177, and 293T cells by HIV-1 carrying no viral
envelope proteins or envelope proteins from either HIV or VSV (results
from two independent experiments). The methods are described in the
legend to Fig. 2. (B) Infection of cell lines HT1080, DU145, and
HeLa-CD4 by HIV-1 NL4-3-EGFP-Env( ) alone or with either
HIV-1LAI envelope proteins or VSV-G (results from two
independent experiments). Cells (5 × 103) were plated
in each well of 24-well culture plates 24 h prior to infection.
Viruses with a p24 titer of 100 ng were added to each well. At day 6 postinfection, EGFP-positive cells were counted visually under a UV
microscope. The cells that were connected to each other, forming a
positive colony, were counted as one infection event. The total numbers
of infection events in each well were counted and divided by
104 (we estimated that the cell numbers in each well
doubled after 24 h in culture) to obtain the percentage of
infection. The AZT control assays were performed by adding 5 µM AZT
to the culture medium 30 min before viral infection, and this
concentration of AZT was maintained in the medium after viral
infection. (C) Infection of CD4 prostate cell line DU145
by various doses of NL4-3-EGFP viruses with or without Env. Cells were
prepared as described in panel B, and viruses with 10 to 100 ng of p24
were added to each well. At day 6 postinfection, EGFP-positive cells
were counted. (D) Infection of CD4 prostate cell line
DU145 with HIV-1 NL4-3-EGFP Env prepared from a stably
transduced CD4+ T-cell line, MOLT4 (see Materials and
Methods). Error bars indicate standard deviations.
|
|

View larger version (111K):
[in this window]
[in a new window]
|
FIG. 4.
UV microscope detection of HIV-1-infected
CD4 cells. (A) CD4 epithelial cell lines
infected by NL4-3-EGFP Env virus with
HIV-1LAI envelope proteins, with no addition of envelope
proteins, or with VSV-G. Photographs were taken at day 6 postinfection.
Cell culturing and HIV-1 infection are described in the legends to Fig.
2 and 3. (B) EGFP-positive cells from cell culture plates of Tu177,
Tu139, and DU145 CD4 cells infected by NL4-3-EGFP
Env virus generated from the stably transduced MOLT4 cell
line. The cell culture plates were prepared as described in the legend
to Fig. 3. Viruses with 20 ng of p24 in 0.5 ml of RPMI medium were
added to each well of cultured cells. EGFP-positive cells were detected
at day 6 postinfection.
|
|
We tested the dose response for CD4
cell infection. The
CD4
cell line DU145 was infected with various doses of
NL4-3-EGFP viruses without or with Env. As Fig. 3C shows, with
increasing titers of viruses, EGFP-positive cells increased
proportionately. Our results indicate that HIV-1 can infect many types
of CD4
cells at low but significant levels. HIV-1 without
Env in our experiments (200 ng of p24/ml) demonstrated approximately
400 tissue EGFP-positive U/ml for DU145 cells, 1,300 EGFP-positive U/ml
for Tu177 cells, and 2,200 EGFP-positive U/ml for Tu139 cells. HIV-1
with Env showed similar infectivity, approximately 300 EGFP-positive U/ml for DU145, 1,100 EGFP-positive U/ml for Tu177, and 1,600 EGFP-positive U/ml for TU139 cells.
To assess the significance of Env-independent infection in more
physiologically relevant cells, we derived cultured primary human oral
epithelial cells from normal gingival tissue. The cells derived from
gingival tissue, NHOK (17), were expanded in cultures for
less than two passages. Gingival cells from two normal individuals were
tested. At day 6 postinfection, 0.6 to 1.2% of the cells were EGFP
positive (Fig. 3B, NHOK). The percentage of HIV-1-infected cells was
higher than that seen with infection of the 293T kidney epithelial cell
line but lower than that seen with infection of the oral epithelial
cell lines Tu139 and Tu177. The susceptibilities of the gingival
epithelial cells to HIV-1 with or without Env proteins were similar.
We also tested virus produced from a CD4+ T-lymphocyte cell
line, MOLT4. The MOLT4 cell line was stably transduced with NL4-3-EGFP Env
. HIV-1 NL4-3-EGFP Env
collected from
this cell line was used for infection of the CD4
cell
lines Tu139, Tu177, and DU145. Significant levels of EGFP-positive cells were detected in all three tested cell lines (Fig. 4B). We
further demonstrated a dose response for EGFP-positive cells following
infection of DU145 cells (Fig. 3D).
The NL4-3-EGFP Env
genome contains all the genes
necessary for virus replication in susceptible cells. We predict that
if infection of susceptible epithelial cells occurred by
Env-independent mechanisms, we would observe ongoing spread of virus
infection in the cultures. Following infection of Tu139 and Tu177, the
culture medium was collected at various times postinfection and assayed for HIV-1 p24. p24 levels increased in the culture medium over time,
indicating that new infectious virus particles were generated from the
infected cells (Fig. 5). These results
are consistent with the increasing number of EGFP-positive cells
observed over time (data not shown). The increase in p24 levels in the
infected-cell culture was inhibited by the addition of AZT. Thus, these
results demonstrate ongoing replication and continued spread of the
virus within the cultures over time in the absence of Env.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 5.
Time course of infection by NL4-3-EGFP Env
virus. Infections of two oral cell lines were performed by the methods
described in the legend to Fig. 2. After infection, cells were washed
twice with serum-free medium, and new culture medium was added. After
1 h of incubation, 330 µl (1/6 volume) of the 2 ml in the wells
was harvested for the p24 assay (day 1), and 330 µl of fresh medium
was added to the wells to maintain the volume. The same procedure was
followed on days 3 and 5 for p24 sample collection. The AZT control
assays were performed by adding 5 µM AZT to the culture medium 30 min
prior to viral infection, and this concentration of AZT was maintained
in the medium throughout the experiment. Error bars indicate standard
deviations.
|
|
One prediction for Env-independent infection is that neutralizing
antibodies should not block infection even for HIV-1 that bears Env. We
tested this prediction by examining the effect of neutralizing
monoclonal antibody IgG1-b12 (NIH AIDS reagent; catalog no. 2640). The
addition of IgG1-b12 efficiently decreased the infection of HeLa-CD4
cells by NL4-3-EGFP bearing the HIV-1LAI envelope protein
(Fig. 6A). However, the addition of this
antibody did not show any neutralization of the ability of the same
virus to infect CD4
cells Tu139 and/or DU145 (Fig. 6B).
As expected, the addition of IgG1-b12 did not neutralize infection of
either Tu139 or DU145 CD4
cells by NL4-3-EGFP
Env
.


View larger version (55K):
[in this window]
[in a new window]
|
FIG. 6.
Neutralization of HIV-1 gp120 by monoclonal antibody
(mAB) IgG1-b12. gp120-specific IgG1-b12 was used to neutralize
NL4-3-EGFP viruses with or without HIV-1 envelope proteins. (A) Flow
cytometric analysis of the infection of HeLa-CD4 cells by NL4-3-EGFP
virus with the HIV-1LAI envelope protein. Significant
neutralization can be seen by comparing the C4 quadrants (0.9 versus
5.9% EGFP-positive cells). (B) Percentage of EGFP-positive cells
following infection by IgG1-b12-treated virus relative to virus treated
identically but without antibody. The percentage of EGFP-positive cells
infected by virus not treated with IgG1-b12 was assigned as 100%. No
EGFP-positive cells were detected on plates of HeLa-CD4 cells infected
by NL4-3-EGFP Env virus, either treated or not treated
with IgG1-b12, so the lane for HeLa-CD4 cells infected by NL4-3-EGFP
Env is empty. Infection methods are described in the
legend to Fig. 3, except that the cells were infected by IgG1-b12- or
mock-treated viruses. EGFP-positive cells were counted by UV
microscopic visualization. For infection of HeLa-CD4 cells, the results
from UV microscopic visualization were also analyzed by
fluorescence-activated cell sorting (A). Two experiments were
performed, with similar results, and results from one experiment are
shown. Each infection was performed in duplicate, and numbers represent
the average for the two wells. The numbers of EGFP-positive cells were
as follows: 1) HeLa-CD4 cells infected by NL4-3-EGFP with
HIVLAI Env, with IgG1-b12, 103 and 82, and without
IgG1-b12, 503 and 443; Tu139 cells infected by NL4-3-EGFP with
HIVLAI Env, with IgG1-b12, 23 and 16, and without IgG1-b12,
8, and 18; Tu139 cells infected by NL4-3-EGFP Env , with
IgG1-b12, 9 and 9, and without IgG1-b12, 10 and 7; DU145 cells infected
by NL4-3-EGFP with HIVLAI Env, with IgG1-b12, 39 and 43, and without IgG1-b12, 41, and 45; and DU145 cells infected by
NL4-3-EGFP Env , with IgG1-b12, 22 and 36, and without
IgG1-b12, 35, and 29.
|
|
 |
DISCUSSION |
With the discovery of HIV-1 coreceptors, it appears that HIV-1 can
infect cells not only via binding to CD4 and subsequent fusion but also
via direct interactions between gp120 and coreceptor molecules, albeit
at a lower efficiency. Although such a mechanism provides a reasonable
explanation for the infection of CD4
cells by HIV-1, it
fails to explain our observation that gp120 is not required for some
infections. Therefore, we propose a different mechanism for HIV-1
infection of CD4 cells, occurring independently of HIV-1 envelope
proteins. It has been reported that cellular membrane proteins are
incorporated into the viral lipid envelope during budding
(12). It is possible that these cellular membrane proteins
in the viral envelope interact with appropriate receptors on the
surface of some target CD4
cells, thus facilitating entry
of the virus into the target cells. The HIV-1 Env protein, gp120, is
not stable, and a significant percentage of HIV-1 virions may lose this
protein from their envelopes shortly after the viral particles are
released from infected cells. Without gp120, these viral particles are
no longer able to infect cells via binding to CD4 molecules but may
still infect cells via the route described above. Indeed, we found that
virions with or without gp120 infected the tested CD4
cells with equal efficiencies. A significant amount of HIV-1 could be
sustained in these CD4
cells and could serve as a
reservoir for HIV-1. In most of our tests, virus with a p24 count of
200 ng/ml is comparable to the virus load in most AIDS patients before
treatments (15). If even 0.1% of CD4
cells in
patients are infected, the total infected CD4
cells
should be greater than 109.
The infection of human CD4
cells by HIV-1 may be
important in disease transmission, latency, and progression. Epithelial
cells lining the respiratory, digestive, and genital tracts provide a
protective boundary against the external environment. Mucosal epithelial cells can form tight junctions that subdivide the plasma membrane into an apical domain, which faces the luminal side, and a
basolateral domain, which faces the connective tissue of the underlying
lamina propria. In such polarized epithelial cells, plasma membrane
proteins may differ significantly at the two surfaces. HIV-1 has been
reported to bud preferentially from the basolateral surface of
polarized epithelial cells (19). The release of virus from
the basolateral domain may play an important role in HIV-1 transmission. However, the mechanisms of HIV-1 entry into patients through the cellular mucosal barrier remain obscure (2). The direct infection of epithelial cells and the subsequent release of
virus from the basolateral domain may be important means of HIV-1 transmission.
The ability of HIV-1 to infect epithelial cells also has direct
implications for vaccine development. We demonstrated that a
conformationally dependent neutralizing antibody could not block HIV-1
infection of the CD4
cells tested. Thus, whether
neutralizing antibodies directed against the HIV-1 envelope can be
fully protective for epithelial cell infection at mucosal surfaces
remains to be examined.
 |
ACKNOWLEDGMENTS |
This study was supported by NIH grants 1R21 AI4267 and 1R01
AI39975 and UCLA Center for AIDS Research grant AI28697.
We thank K. Grovit-Ferbas, S. Kung, and K. Morizono for technical
assistance; S. Hunt-Gerardo, W. Aft, L. Duarte, and R. Taweesup for
preparation of the manuscript; and Z. Wen for cell culture and virus preparation.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medicine, Department of Microbiology and Immunology, and UCLA AIDS
Institute, UCLA School of Medicine, 10833 Le Conte Ave., Los Angeles,
CA 90095. Phone: (310) 825-4793. Fax: (310) 794-7682. E-mail: rtaweesu{at}ucla.edu.
 |
REFERENCES |
| 1.
|
Bhat, S.,
S. L. Spitalnik,
F. Gonzalez-Scarano, and D. H. Silberberg.
1991.
Galactosyl ceramide or a derivative is an essential component of the neural receptor for human immunodeficiency virus type 1 envelope glycoprotein gp120.
Proc. Natl. Acad. Sci. USA
88:7131-7134[Abstract/Free Full Text].
|
| 2.
|
Bomsel, M.
1997.
Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier.
Nat. Med.
3:42-47[CrossRef][Medline].
|
| 3.
|
Cook, D. G.,
J. Fantini,
S. L. Spitalnik, and F. Gonzalez-Scarano.
1994.
Binding of human immunodeficiency virus type 1 (HIV-1) gp120 to galactosylceramide (GalCer): relationship to the V3 loop.
Virology
201:206-214[CrossRef][Medline].
|
| 4.
|
Delezay, O.,
N. Koch,
N. Yahi,
D. Hammache,
C. Tourres,
C. Tamalet, and J. Fantini.
1997.
Co-expression of CXCR4/fusin and galactosylceramide in the human intestinal epithelial cell line HT-29.
AIDS
11:1311-1318[CrossRef][Medline].
|
| 5.
|
Doranz, B. J.,
J. Rucker,
Y. Yi,
R. J. Smyth,
M. Samson,
S. C. Peiper,
M. Parmentier,
R. G. Collman, and R. W. Doms.
1996.
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.
Cell
85:1149-1158[CrossRef][Medline].
|
| 6.
|
Dragic, T.,
V. Litwin,
G. P. Allaway,
S. R. Martin,
Y. Huang,
K. A. Nagashima,
C. Cayanan,
P. J. Maddon,
R. A. Koup,
J. P. Moore, and W. A. Paxton.
1996.
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.
Nature
381:667-673[CrossRef][Medline].
|
| 7.
|
Edinger, A. L.,
J. L. Mankowski,
B. J. Doranz,
B. J. Margulies,
B. Lee,
J. Rucker,
M. Sharron,
T. L. Hoffman,
J. F. Berson,
M. C. Zink,
V. M. Hirsch,
J. E. Clements, and R. W. Doms.
1997.
CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain.
Proc. Natl. Acad. Sci. USA
94:14742-14747[Abstract/Free Full Text].
|
| 8.
|
Fantini, J.,
D. Hammache,
O. Delezay,
G. Pieroni,
C. Tamalet, and N. Yahi.
1998.
Sulfatide inhibits HIV-1 entry into CD4 /CXCR4+ cells.
Virology
246:211-220[CrossRef][Medline].
|
| 9.
|
Fantini, J.,
N. Yahi, and J. C. Chermann.
1991.
Human immunodeficiency virus can infect the apical and basolateral surfaces of human colonic epithelial cells.
Proc. Natl. Acad. Sci. USA
88:9297-9301[Abstract/Free Full Text].
|
| 10.
|
Feng, Y.,
C. C. Broder,
P. E. Kennedy, and E. A. Berger.
1996.
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.
Science
272:872-877[Abstract].
|
| 11.
|
Furuta, Y.,
K. Eriksson,
B. Svennerholm,
P. Fredman,
P. Horal,
S. Jeansson,
A. Vahlne,
J. Holmgren, and C. Czerkinsky.
1994.
Infection of vaginal and colonic epithelial cells by the human immunodeficiency virus type 1 is neutralized by antibodies raised against conserved epitopes in the envelope glycoprotein gp120.
Proc. Natl. Acad. Sci. USA
91:12559-12563[Abstract/Free Full Text].
|
| 12.
|
Gelderblom, H.,
H. Reupke,
T. Winkel,
R. Kunze, and G. Pauli.
1987.
MHC-antigens: constituents of the envelopes of human and simian immunodeficiency viruses.
Z. Naturforsch.
42:1328-1334.
|
| 13.
|
Harouse, J. M.,
S. Bhat,
S. L. Spitalnik,
M. Laughlin,
K. Stefano,
D. H. Silberberg, and F. Gonzalez-Scarano.
1991.
Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide.
Science
253:320-323[Abstract/Free Full Text].
|
| 14.
|
Harouse, J. M.,
C. Kunsch,
H. T. Hartle,
M. A. Laughlin,
J. A. Hoxie,
B. Wigdahl, and F. Gonzalez-Scarano.
1989.
CD4-independent infection of human neural cells by human immunodeficiency virus type 1.
J. Virol.
63:2527-2533[Abstract/Free Full Text].
|
| 15.
|
Ho, D. D.,
T. Moudgil, and M. Alam.
1989.
Quantitation of human immunodeficiency virus type 1 in the blood of infected persons.
N. Engl. J. Med.
321:1621-1625[Abstract].
|
| 16.
|
Howell, A. L.,
R. D. Edkins,
S. E. Rier,
G. R. Yeaman,
J. E. Stern,
M. W. Fanger, and C. R. Wira.
1997.
Human immunodeficiency virus type 1 infection of cells and tissues from the upper and lower human female reproductive tract.
J. Virol.
71:3498-3506[Abstract].
|
| 17.
|
Min, B. M.,
J. H. Baek,
K. H. Shin,
C. N. Gujuluva,
H. M. Cherrick, and N. H. Park.
1994.
Inactivation of the p53 gene by either mutation or HPV infection is extremely frequent in human oral squamous cell carcinoma cell lines.
Eur. J. Cancer
30B:338-345[CrossRef].
|
| 18.
|
Naldini, L.,
U. Blomer,
F. H. Gage,
D. Trono, and I. M. Verma.
1996.
Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector.
Proc. Natl. Acad. Sci. USA
93:11382-11383[Abstract/Free Full Text].
|
| 19.
|
Owens, R. J., and R. W. Compans.
1989.
Expression of the human immunodeficiency virus envelope glycoprotein is restricted to basolateral surfaces of polarized epithelial cells.
J. Virol.
63:978-982[Abstract/Free Full Text].
|
| 20.
|
Owens, R. J.,
J. W. Dubay,
E. Hunter, and R. W. Compans.
1991.
Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells.
Proc. Natl. Acad. Sci. USA
88:3987-3991[Abstract/Free Full Text].
|
| 21.
|
Potempa, S.,
L. Picard,
J. D. Reeves,
D. Wilkinson,
R. A. Weiss, and S. J. Talbot.
1997.
CD4-independent infection by human immunodeficiency virus type 2 strain ROD/B: the role of the N-terminal domain of CXCR-4 in fusion and entry.
J. Virol.
71:4419-4424[Abstract].
|
| 22.
|
Qureshi, M. N.,
C. E. Barr,
I. Hewlitt,
R. Boorstein,
F. Kong,
O. Bagasra,
L. E. Bobroski, and B. Joshi.
1997.
Detection of HIV in oral mucosal cells.
Oral Dis.
3(Suppl. 1):S73-S78.
|
| 23.
|
Sadaie, M. R.,
V. S. Kalyanaraman,
R. Mukopadhayaya,
E. Tschachler,
R. C. Gallo, and F. Wong-Staal.
1992.
Biological characterization of noninfectious HIV-1 particles lacking the envelope protein.
Virology
6:1257-1263.
|
| 24.
|
Tan, X., and D. M. Phillips.
1996.
Cell-mediated infection of cervix derived epithelial cells with primary isolates of human immunodeficiency virus.
Arch. Virol.
141:1177-1189[CrossRef][Medline].
|
| 25.
|
Yahi, N.,
J. M. Sabatier,
P. Nickel,
K. Mabrouk,
F. Gonzalez-Scarano, and J. Fantini.
1994.
Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells.
J. Biol. Chem.
269:24349-24353[Abstract/Free Full Text].
|
Journal of Virology, December 2000, p. 10994-11000, Vol. 74, No. 23
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Wang, Q., Pang, S.
(2008). An intercellular adhesion molecule-3 (ICAM-3) -grabbing nonintegrin (DC-SIGN) efficiently blocks HIV viral budding. FASEB J.
22: 1055-1064
[Abstract]
[Full Text]
-
Herzberg, M.C., Weinberg, A., Wahl, S.M.
(2006). (C3) The Oral Epithelial Cell and First Encounters with HIV-1. ADR
19: 158-166
[Abstract]
[Full Text]
-
Zerhouni, B., Nelson, J. A. E., Saha, K.
(2004). Isolation of CD4-Independent Primary Human Immunodeficiency Virus Type 1 Isolates That Are Syncytium Inducing and Acutely Cytopathic for CD8+ Lymphocytes. J. Virol.
78: 1243-1255
[Abstract]
[Full Text]
-
Burrer, R., Haessig-Einius, S., Aubertin, A.-M., Moog, C.
(2003). Polyclonal Immunoglobulin G from Patients Neutralizes Human Immunodeficiency Virus Type 1 Primary Isolates by Binding Free Virions, but without Interfering with an Initial CD4-Independent Attachment of the Virus to Primary Blood Mononuclear Cells. J. Virol.
77: 11385-11397
[Abstract]
[Full Text]
-
Gould, S. J., Booth, A. M., Hildreth, J. E. K.
(2003). The Trojan exosome hypothesis. Proc. Natl. Acad. Sci. USA
100: 10592-10597
[Abstract]
[Full Text]
-
Callahan, M. K., Popernack, P. M., Tsutsui, S., Truong, L., Schlegel, R. A., Henderson, A. J.
(2003). Phosphatidylserine on HIV Envelope Is a Cofactor for Infection of Monocytic Cells. J. Immunol.
170: 4840-4845
[Abstract]
[Full Text]
-
Qin, X.-F., An, D. S., Chen, I. S. Y., Baltimore, D.
(2003). Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl. Acad. Sci. USA
100: 183-188
[Abstract]
[Full Text]
-
Johnston, J. B., Power, C.
(2002). Feline Immunodeficiency Virus Xenoinfection: the Role of Chemokine Receptors and Envelope Diversity. J. Virol.
76: 3626-3636
[Abstract]
[Full Text]
-
Carreno, M.-P., Chomont, N., Kazatchkine, M. D., Irinopoulou, T., Krief, C., Mohamed, A.-S., Andreoletti, L., Matta, M., Belec, L.
(2002). Binding of LFA-1 (CD11a) to Intercellular Adhesion Molecule 3 (ICAM-3; CD50) and ICAM-2 (CD102) Triggers Transmigration of Human Immunodeficiency Virus Type 1-Infected Monocytes through Mucosal Epithelial Cells. J. Virol.
76: 32-40
[Abstract]
[Full Text]